Precision BioSciences Inc (DTIL) stock
DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/3058% above fair value
$7.10+0.05 (+0.71%)
Close on Nov 18, 2026Market cap $195.97MP/E –Yield –
Precision BioSciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Precision BioSciences's operating income for the twelve months ending Jun 30, 2026 was -$36.40M. For fiscal 2025 it was -$52.15M. The highest annual figure on record is -$26.16M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$52.15M | – |
| FY2024 | Dec 31, 2024 | -$26.16M | – |
| FY2023 | Dec 31, 2023 | -$43.74M | – |
| FY2022 | Dec 31, 2022 | -$62.31M | – |
| FY2021 | Dec 31, 2021 | -$39.38M | – |
| FY2020 | Dec 31, 2020 | -$109.83M | – |
| FY2019 | Dec 31, 2019 | -$87.20M | – |
| FY2018 | Dec 31, 2018 | -$47.91M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.16M | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.08M | – |
| Q4 FY2025 | Dec 31, 2025 | $12.51M | – |
| Q3 FY2025 | Sep 30, 2025 | -$20.67M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.88M | -190.6% |
| Q1 FY2025 | Mar 31, 2025 | -$22.11M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.85M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.28M | – |
| Q2 FY2024 | Jun 30, 2024 | $24.15M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.19M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.89M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.13M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.35M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.11M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.68M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.55M | -236.6% |
| Q1 FY2022 | Mar 31, 2022 | -$27.34M | – |
| Q4 FY2021 | Dec 31, 2021 | -$30.72M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.54M | – |
| Q2 FY2021 | Jun 30, 2021 | $21.63M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.74M | – |
| Q4 FY2020 | Dec 31, 2020 | -$23.48M | – |
| Q3 FY2020 | Sep 30, 2020 | -$26.04M | – |
| Q2 FY2020 | Jun 30, 2020 | -$32.81M | – |
| Q1 FY2020 | Mar 31, 2020 | -$27.50M | – |
| Q4 FY2019 | Dec 31, 2019 | -$21.86M | – |
| Q3 FY2019 | Sep 30, 2019 | -$21.98M | – |
| Q2 FY2019 | Jun 30, 2019 | -$23.87M | – |
| Q1 FY2019 | Mar 31, 2019 | -$19.49M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.11M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.45M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.13M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.24M | – |
See a number that looks wrong?